

NEUROPATHIC PAIN

Vanja Bašić Kes¹, Mira Ivanković², Milan Bitunjac³, Valbona Govori⁴,
Vida Demarin¹

¹Department of neurology, University hospital, Sestre milosrdnice, Zagreb, Croatia

²Department of neurology, General hospital, Dubrovnik, Croatia

³Department of neurology, General hospital, Slavonski Brod, Croatia

⁴Department of neurology, University Clinical Center, Prishtina, Kosovo

Summary

Neuropathic pain refers to pain that originates from pathology of the nervous system. Common causes of neuropathic pain are diabetes mellitus, reactivation of herpes zoster, nerve compression or radiculopathy, alcohol, chemotherapy or abuse of some drugs and trigeminal neuralgia.

Specific symptoms of neuropathic pain are mechanical allodynia and cold hyperalgesia.

Drugs to treat neuropathic pain can be divided into adjuvant analgesics (antidepressants and anticonvulsants), opioids and topical agents. The use of multiple drug therapies is common in practice.

Despite considerable increase in the number of randomized placebo-controlled trials in neuropathic pain over the last few years, the medical treatment of neuropathic pain is still far from being satisfactory, with less than half of patients achieving significant benefit with any pharmacological drug.

Key words: neuropathic pain; etiology; treatment.

INTRODUCTION

Neuropathic pain is defined as 'pain initiated or caused by a primary lesion or dysfunction of the nervous system' [1]. It can be a debilitating and difficult condition to treat and is often resistant to simple analgesics, requiring additional analgesic approaches [2]. It is not only devastating for patients but also places considerable demands on society, including financial burdens relating to health-care costs, workplace disruption, disability and benefits [3].

Corresponding author: Vanja Bašić Kes
e-mail: vanjakes@net.hr

Neuropathic pain mechanisms

Neuropathic pain is generated by electrical hyperactivity of neurons along the pain pathways. The sensory pathway consists of at least three neurons, and lesions anywhere along the pathway can lead to neuropathic pain. Changes in expression of neuronal ion channels and receptors, synaptic connectivity, and anatomy all contribute to neuropathic pain (neural plasticity) [4,5].

Clinical investigations of pain mechanisms are labor intensive and require specialized equipment; thus, they are not yet practical for routine clinical use. Even in specialized pain research settings, it is difficult to identify specific neuropathic pain mechanisms. A simple focal peripheral nerve injury unleashes a range of peripheral and central nervous system processes that can all contribute to persistent pain and abnormal sensation [6].

Inflammation, reparatory mechanisms of neural tissues in response to injury, and the reaction of adjacent tissues to injury lead to a state of hyperexcitability in primary afferent nociceptors, a phenomenon termed peripheral sensitization. In turn, central neurons innervated by such nociceptors undergo dramatic functional changes including a state of hyperexcitability termed central sensitization. Normally these sensitization phenomena extinguish themselves as the tissue heals and inflammation subsides. However, when primary afferent function is altered in an enduring way by injury or disease of the nervous system, these processes persist and may be highly resistant to treatment [7,8].

Injury or permanent loss of primary afferent fibers (deafferentation) differentiates peripheral neuropathic pain from other types of pain. Positive sensory phenomena (spontaneous pain, allodynia, and hyperalgesia) that are characteristic of patients with neuropathic pain are likely to have many underlying mechanisms, including ectopic generation of impulses as well as the de novo expression of neurotransmitters and their receptors and ion channels. Direct injury to central structures may permanently alter sensory processing, and in some patients it causes central neuropathic pain and dysesthesias. The mechanisms underlying central neuropathic pain, however, are still unclear [9-11].

Increased understanding of the underlying mechanisms has allowed the identification of new pharmacological targets and the development of new neuropathic medications but, at present, this has not helped to work out which patients are likely to respond to individual treatments.

Diagnosis of neuropathic pain

Neuropathic pain syndromes typically have both negative and positive sensory symptoms and signs [12]. Nonsensory neurological symptoms and signs

depend on the underlying cause and may independently contribute to pain and disability. Although neuropathic pain has been defined by the International Association for the Study of Pain as pain “initiated or caused by a primary lesion or dysfunction in the nervous system,” several investigators have recently argued that the inclusion of the term dysfunction makes this definition vague and unacceptably broad [5]. A proposed solution is to define neuropathic pain as pain caused by a lesion of the peripheral or central nervous system (or both) manifesting with sensory symptoms and signs. Demonstrating a lesion of the nervous system compatible with particular symptoms and signs provides strong support for considering the pain to be neuropathic. However, when no lesion can be demonstrated, the limits of current diagnostic technology do not always allow the possibility of neuropathic pain to be excluded. The diagnosis of neuropathic pain is based on a medical history, review of systems, physical and neurological examination, and appropriate laboratory studies including blood and serologic tests, magnetic resonance imaging, and electrophysiologic studies [13]. In some instances, nerve or skin biopsy is necessary to directly visualize nerve fibers.

Our ability to translate pain complaints and sensory findings into specific pathophysiologic mechanisms that have treatment implications is in its infancy [14,15].

TREATMENT

Regardless of the cause, neuropathic pain affects multiple aspects of a patient’s life. The management of neuropathic pain involves a multidisciplinary approach. The therapy of neuropathic pain includes use of both non-interventional (pharmacological, psychological, and physical therapy) as well as interventional therapies.

Without concern for diagnosis, rehabilitation, and psychosocial issues, treatment has a limited chance of success. For peripheral nerve lesions, mobilization is needed to prevent trophic changes, disuse atrophy, and joint ankylosis. Surgery may be needed to alleviate compression. Psychologic factors must be constantly considered from the start of treatment. Anxiety and depression must be treated appropriately. When dysfunction is entrenched, patients may benefit from the comprehensive approach provided by a pain clinic.

Pharmacotherapy

The best clinical approach to applied pharmacology currently incorporates empiric observation and identification of possible mechanisms of the neuro-

pathic lesion and then uses the best available pharmacologic information to match these potential disease mechanisms with putative drug mechanisms. Although monotherapy is the ideal approach, rational polypharmacy is often pragmatically used.

Several classes of drugs are moderately effective, but complete or near-complete relief is unlikely. Antidepressants and anticonvulsants are most commonly used. Evidence of efficacy is strong for several antidepressants and anticonvulsants.

Opioid analgesics can provide some relief but are less effective than for nociceptive pain; adverse effects may prevent adequate analgesia. Topical drugs and a lidocaine – containing patch may be effective for peripheral syndromes. Sympathetic blockade is usually ineffective except for some patients with complex regional pain syndrome [16,17].

ANTIDEPRESSANTS

The tricyclic antidepressants (TCAs) are often regarded as first-line drugs for neuropathic pain. A recent systematic review of the literature, in which numbers needed to treat (NNTs) of treatments for different neuropathic pain syndromes were calculated, has found TCAs the most efficacious drugs for neuropathic pain (NNT 3.1; 95% confidence interval (CI) 2.7-3.7) [19,20]. This is based on results from no less than 15 placebo-controlled designed trials, which have uniformly demonstrated efficacy of amitriptyline, nortriptyline, desipramine, chlomipramine, imipramine and maprotiline, at a daily dose range of 30-200mg, for PHN and DPN [21]. The main drawback of these trials is the small number of recruited patients in each of them. Yet, taken together, they provide strong level of evidence for efficacy. Notably, two small trials have found TCAs superior to placebo for central post-stroke pain and post-mastectomy neuropathic pain, whereas several others failed to demonstrate efficacy for spinal-cord injury pain, Human Immunodeficiency Virus (HIV) neuropathy and phantom limb pain. Unfortunately, TCAs are associated with numerous adverse events and are not tolerated by many patients. When used, slow titration is required, especially in the elderly [22].

Two trials have demonstrated efficacy of the selective serotonin reuptake inhibitors (SSRIs) citalopram and paroxetine (both at 40mg/day) in DPN [23]. In another trial, fluoxetine was equal to placebo [24].

The selective serotonin and norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine are newer antidepressants that have shown effectiveness

for DPN at daily doses of 150- 225mg and 60-120mg, respectively. The NNTs of 4.6 (CI 2.9-10.6) for venlafaxine and 5.2 (CI 3.7-8.5) for duloxetine are superior to that of the SSRIs but inferior compared to the TCAs [6]. In two large randomized controlled trials (RCTs) duloxetine also significantly improved sleep and quality of life. Its most common adverse events are nausea, somnolence, dizziness and constipation, which all tend to decrease over time. The drug should not be used concomitantly with monoamine oxidase (MAO) inhibitors or in patients with impaired liver function. One notable advantage of the antidepressants (with the exception of venlafaxine) is that they can be administered once daily [25,26].

Side effects of TCAs

The most common side-effects of tricyclic antidepressants (TCA) are dry mouth, constipation, sweating, dizziness, disturbed vision, drowsiness, palpitation, orthostatic hypotension, sedation and urinary hesitation. More selective TCA such as nortriptyline are better tolerated than the non-selective ones, with less anticholinergic effects and sedation. A suspected association between TCA treatment and sudden cardiac death has raised concern; a recent epidemiological study found a slight increase in sudden cardiac death with TCA doses superior to 100 mg/day. Therefore caution is recommended for older patients, particularly those with cardiovascular risk factors.

Serotonin-noradrenaline reuptake inhibitors (duloxetine, venlafaxine) are safer to use than TCAs and are a better option in patients with cardiac disease. The relative risk for withdrawal due to side-effects is weak and there is no need for drug level monitoring. The most frequently observed adverse events with duloxetine are nausea, vomiting, constipation, somnolence, dry mouth, increased sweating, loss of appetite and weakness. Although immediate release venlafaxine is associated with adverse central nervous system (CNS) and somatic symptoms such as agitation, diarrhea, increased liver enzymes, hypertension and hyponatremia the extended release formulation seems to be far more tolerable, the main side-effects being gastrointestinal disturbances

ANTICONVULSANTS

In addition to the antidepressants, selected anticonvulsants are often regarded as first line drugs for neuropathic pain. RCTs have shown efficacy of gabapentin, pregabalin, lamotrigine, carbamazepine and, to a lesser extent, a few other anticonvulsants. Yet, with the exception of trigeminal neuralgia, the challenge of 50% pain relief in more than half of these patients is rarely met [26,27].

The most extensively studied drug in this class is pregabalin, which has shown efficacy for PHN and DPN in a large number of multicentre RCTs. The effective daily dose of 300-600mg can reduce pain and improve sleep, functioning and quality of life. Pregabalin can be rapidly titrated. Unfortunately, the drug has not been studied in other types of neuropathic pain. The most commonly reported adverse events occurring during all controlled clinical trials were dizziness, somnolence, dry mouth and edema. Weight gain can also be a problem in some patients [28].

There is also strong evidence for efficacy of gabapentin (900-3600mg/day) for PHN and DPN. Although less broadly studied in other syndromes, gabapentin has shown efficacy in HIV-associated painful neuropathy, pain in Guillain-Barre's syndrome, phantom limb pain, cancer related neuropathic pain and complex regional pain syndrome type I [27].

RCTs have shown efficacy of lamotrigine for PDN, central post stroke pain, trigeminal neuralgia (TN) and mixed neuropathies, and of carbamazepine and oxcarbazepine for TN, PDN and mixed neuropathies. The need for a relatively slow titration and the adverse effect profile of these drugs make them a second line of anti-epileptic treatment for these conditions, except for TN. Equivocal or negative (active therapy not superior to placebo) results were reported with lamotrigine for spinal cord injury pain, HIV-related neuropathy and mixed neuropathies with topiramate for PDN as well as valproate for DPN and for spinal cord injury pain [29].

Side effects of anticonvulsants

Carbamazepine (CBZ) entails frequent adverse events, which include sedation, dizziness, gait abnormalities. Liver enzymes, blood cells, platelets and sodium levels must be monitored for at least during 1 year, because of possible risk for hepatitis-anaplastic effects or hyponatremia. Induction of microsomal enzyme systems may influence the metabolism of several drugs. In contrast to CBZ, oxcarbazepine (OXC) does not entail enzymatic induction and there is little risk for crossed cutaneous allergy. In the first months of treatment, sodium levels must be monitored because OXC, like CBZ induces hyponatraemia, particularly in the elderly (6% in a cohort of 54 patients). As regards other side-effects, although a better tolerance has been claimed with OXC compared with CBZ, this notion lacks consistent evidence from class I trials. In a recent trial in diabetic painful polyneuropathy, 27.5% of the OXC group discontinued treatment due to central or gastrointestinal side-effects versus 8% with the placebo.

The most common side-effects of gabapentin (GBP) and pregabalin include dizziness, somnolence, peripheral edema, and dry mouth, with a similar frequency for both drugs. Whilst GBP is widely accepted as highly tolerable even at high dosages (>2400 mg), the reports on pregabalin change remarkably with the daily dose: with 150 to 300 mg there is almost no difference with placebo, whilst the withdrawal rate reaches 20% with 600 mg.

Lamotrigine is generally well tolerated. Side-effects include dizziness, nausea, headache and fatigue. However, it may induce potentially severe allergic skin reactions. Lamotrigine should not be used in combination with valproate.

OPIOIDS

Eight RCTs tested the efficacy of oral opioids for PDN, PHN, phantom pain and neuropathic pain of diverse etiologies. Four drugs were tested: morphine, oxycodone, methadone and levorphanol. All trials reported that opioids were efficacious in reducing spontaneous neuropathic pain by demonstrating either superiority over placebo or a dose-dependent analgesic response. Six of the eight studies were recently pooled to a meta-analysis, which found a mean pain intensity to be 14 points lower in opioid-treated patients than in those treated with placebo (95% C.I. -18 to -10; $p < 0.001$) [16,17]. The overall NNT of opioids for neuropathic pain is 2.5 (CI 2.0-3.2). Secondary outcome parameters such as physical and mental health, sleep and disability were measured in parts of these trials and yielded inconsistent results. Tramadol, which is not a typical opioid, yet has a weak affinity for opioid receptors, has been effective for DPN and PHN with NNT of 3.9 (CI 2.7-6.7) [5]. Common adverse events of opioids include nausea, constipation, dizziness and drowsiness, had seen an average of 8 different physicians prior to referral to the pain clinic [30,31].

Side effects

The most common side-effects of opioids are constipation, sedation, nausea, dizziness and vomiting. The risk of cognitive impairment has been reported to be negligible, although morphine may impair attention at very high dosages. Tramadol has been reported to induce dizziness, dry mouth, nausea, constipation and somnolence with significantly more dropouts compared with placebo. There is an increased risk of seizures in patients with a history of epilepsy or receiving drugs which may reduce the seizure threshold. Serotonergic syndrome (various combinations of myoclonus, rigidity, hyperreflexia, shivering, confusion, agitation, restlessness, coma, autonomic instability, fever, nausea, diar-

rhoea, flushing, and rarely, rhabdomyolysis and death) may occur if tramadol is used as an add-on treatment to other serotonergic medications (particularly selective serotonin reuptake inhibitors [SSRIs]).

TOPICAL AGENTS

Topical capsaicin cream has shown efficacy for DPN and PHN but its use is associated with burning, particularly during the first weeks of treatment. This can be problematic, especially for patients who experience allodynia in the first place. Application of topical lidocaine patches has been found effective for PHN in three short-term RCTs and can also be used in patients with other focal peripheral neuropathies [32,33].

DRUG COMBINATIONS

While combinations of drugs with different mechanisms of action are commonly used in clinical practice, only one trial tested the efficacy and safety of a combination of two drugs, and found that gabapentin plus morphine was more efficacious and safer than each drug alone [16]. This trial implies the possibility that polypharmcotherapy could enhance analgesia with fewer side effects.

NON-INVASIVE THERAPIES

One of the simplest forms of non-invasive treatment for pain is transcutaneous electrical nerve stimulation (TENS). This has been used since the 1960s, following the development of the gate control theory of pain transmission by Melzack and Wall [8]. The technique is based on the interaction between small and large afferent fibers, which converge on the dorsal horn neurons before projecting to higher centers, and is a useful adjunctive treatment that is virtually free from adverse effects [34].

INVASIVE THERAPIES

The range of neurosurgical techniques used to treat neuropathic pain has increased over time, and includes nerve modulation (e.g., dorsal column stimulation) as well as neural ablation [34]. Numerous ablative surgical techniques to destroy nerves have been described, including nerve avulsion or section, dorsal rhizotomy, spinal dorsal root entry zone lesions, spinothalamic tractotomies, thalamotomies, cingulotomy, frontal lobotomy, and even destruction of the primary sensory cortex. However, these treatments are generally not recom-

mended as they cause more damage to the nervous system, which can intensify the neuropathic pain. Furthermore, none of these surgical techniques has been found to be uniformly successful in treating patients with neuropathic pain. Indeed, there are many examples in the literature of patients who have undergone surgical therapies to treat pain (e.g., due to nerve injury, trigeminal neuralgia, amputation, or post-herpetic neuralgia), only to find that surgery has exacerbated their original pain.

An invasive treatment regimen that is supported by some clinical evidence, and a fairly convincing rationale, is spinal cord dorsal column stimulation. As with TENS, this technique attempts to modulate rostral nociceptive transmission in the spinal cord by stimulation of the large diameter nerve fibers. Success depends on patient selection, and it is generally accepted that patients also suffering some ischemic pain are particularly suited to this method of treatment [35]. The major advantage of this technique is that nerves are not deliberately damaged. Similarly, clinical evidence supports the use of microvascular decompression in providing relatively good long-term outcome for patients with trigeminal neuralgia [36]. Temporary nerve blocks achieved by injection of local anesthetic (e.g., lidocaine), are still sometimes used, though efficacy is controversial and few placebo-controlled trials of this therapy have been performed [5].

The available data clearly indicate that approaches to the clinical management of neuropathic pain vary according to whether the patient is being treated by a pain specialist or by a non-specialist. While non-specialists tend to treat individual symptoms, pain specialists are more likely to select a drug therapy that is targeted towards the mechanisms that are presumed to be causing pain in an individual patient or the anti-neuralgic mechanisms of various drugs [6]. The available data clearly indicate that patients treated in specialized pain clinics are more likely to receive therapies with proven efficacy for the treatment of neuropathic pain than those treated in non-specialist clinics [37-40]

Literature

- [1] *Schmader KE*. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. *Clin J Pain*. 2002;18:350-354.
- [2] *Bowsher D*. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. *Eur J Pain*. 1999;3:335-342. *Backonja MM, Galer BS*. Pain assessment and evaluation of patients who have neuropathic pain. *Neurol Clin*. 1998;16:775-789.
- [3] *Bennett GJ*. Neuropathic pain. In: *Wall PD, Melzack R. Textbook of Pain*. 3rd ed. Edinburgh, Scotland: Churchill Livingstone; 1994:201-224.

- [4] T.E. Smith and M.S. Chong, Neuropathic pain. *Hosp Med* 61 (2000), pp. 760–766.
- [5] Woolf CJ, Mannion J. Neuropathic pain: etiology, symptoms, mechanisms, and management. *Lancet* 353 (1999), pp. 1959–1964. F.
- [6] Orza, M.V. Boswell and S.K. Rosenberg, Neuropathic pain: Review of mechanisms and pharmacologic management. *NeuroRehabilitation* 14 (2000), pp. 15–23.
- [7] R. Melzack and P.D. Wall, Pain mechanisms: a new theory. *Science* 150 (1965), pp. 971–979.
- [8] Haythornthwaite JA, Benrud-Larsen LM. Psychological aspects of neuropathic pain. *Clin J Pain*. 2000;16:S101-S105.
- [9] Woolf CJ, Max MB. Mechanism-based pain diagnosis. *Anesthesiology*. 2001;95:241-249.
- [10] Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. *Pain*. 2003;102:1-8.
- [11] P. Hansson, Neuropathic pain: clinical characteristics and diagnostic workup. *Eur J Pain* 6 (2002), pp. 47–50.
- [12] G.T. Carter and B.S. Galer, Advances in the management of neuropathic pain. *Phys Med Rehabil Clin N Am* 12 (2001), pp. 447–459.
- [13] F. Orza, M.V. Boswell and S.K. Rosenberg, Neuropathic pain: Review of mechanisms and pharmacologic management. *NeuroRehabilitation* 14 (2000), pp. 15–23.
- [14] A.J.M. Boulton, F.A. Gries and J.A. Jervell, Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. *Diabet Med* 15 (1998), pp. 508–514.
- [15] Finnerup NB, Otto M, McQuay HJ et al., “Algorithm for neuropathic pain treatment: an evidence based proposal”, *Pain* (2005);118: pp. 289–305.
- [16] Attal N, Cruccu G, Haanpää M et al., “EFNS guidelines on pharmacological treatment of neuropathic pain”, *Eur J Neurol* (2006);13: pp. 1–17.
- [17] Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. *Pain*. 1999;83:389-400.
- [18] Watson CPN, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. *Neurology*. 1998;51:1166-1171.
- [19] McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. *Pain*. 1996;68:217-227.
- [20] Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. *Neurology*. 2000;55:915-920.
- [21] Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. *J Pain Symptom Manage*. 2000;20:449-458.

- [22] *Sindrup SH, Gram LE, Brosen K, et al.*, "The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms", *Pain* (1990);42: pp. 135-144.
- [23] *Max MB, Lynch SA, Muir J, et al.*, "Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy", *N Engl J Med* (1992);326: pp. 1250-1256.
- [24] *Sindrup SH, Bach FW, Madsen C, Gram LE, Jensen TS.* Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. *Neurology*. 2003;60:1284-1289.
- [25] *Tasmuth T, Hartel B, Kalso E.* Venlafaxine in neuropathic pain following treatment of breast cancer. *Eur J Pain*. 2002;6:17-24.
- [26] *Dworkin RH, Corbin AE, Young JP, et al.* Pregabalin for the treatment of post-herpetic neuralgia: a randomized, placebo-controlled trial. *Neurology*. 2003;60:1274-1283.
- [27] *Watson CPN, Babul N.* Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. *Neurology*. 1998;50:1837-1841.
- [28] *Gimbel JS, Richards P, Portenoy RK.* Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. *Neurology*. 2003;60:927-934.
- [29] *Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D.* Oral opioid therapy for chronic peripheral and central pain. *N Engl J Med*. 2003;348:1223-1232.
- [30] *Rowbotham MC, Davies PS, Verkempinck C, Galer BS.* Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. *Pain*. 1996;65:39-44.
- [31] *Galer BS, Rowbotham MC, Perander J, Friedman E.* Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. *Pain*. 1999;80:533-538.
- [32] *Devers A, Galer BS.* Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. *Clin J Pain*. 2000;16:205-208.
- [33] *M. Sindou and P. Mertens,* Neurosurgical management of neuropathic pain. *Strotaact Funct Neurosurg* 75 (2000), pp. 76-80.
- [34] *L.E. Augustinsson, C.A. Carlsson, J. Holm et al.,* Epidural electrical stimulation in severe limb ischaemia. *Ann Surg* 202 (1985), pp. 104-110.
- [35] *J.M. Zakrewska,* Trigeminal neuralgia. In: *J.M. Zakrewska and S.D. Harrison, Editors, Assessment and management of orofacial pain. Pain research and clinical management series; Vol. 14,* Elsevier Science, Amsterdam (2002).
- [36] *M. Strumpf, M. Zenz and A. Willweber-Strumpf,* Analysis of the therapy of chronic pain. A comparison of previous therapy and specialized pain therapy. *Anesthesist* 42 (1993), pp. 169-174.

- [37] H.T. Davies, I.K. Crombie and W.A. Macrae, Why use a pain clinic. Management of neurogenic pain before or after referral. *J R Soc Med* 87 (1994), pp. 382–385.
- [38] Turk DC. Customizing treatment for chronic pain patients: who, what and why? *Clin J Pain*. 1990;6:255-270.
- [39] Demarin V, Basić-Kes V, Zavoreo I, Bosnar-Puretić M, Rotim K, Lupret V, Perić M, Ivanec Z, Fumić L, Lusić I, Aleksić-Shihabis A, Kovac B, Ivanković M, Skobić H, Maslov B, Bornstein N, Niederkorn K, Sinanović O, Rundek T. Ad hoc Committee of the Croatian Society for Neurovascular Disorders; Croatian Medical Association. Recommendations for neuropathic pain treatment. *Acta Clin Croat*. 2008 Sep;47(3):181-91.
- [40] Bašić Kes V, Demarin V. Recommendations for treatment of neuropathic pain. *Acta Med Croatica*. 2008 May;62(2):237-40.

Sažetak

Neuropatska bol

Neuropatska bol nastaje kao posljedica disfunkcije perifernog ili centralnog živčanog sustava. Najčešći uzroci neuropatske boli su diabetes melitus, reaktivacija herpes zoster infekcije, kompresija živaca ili radikulopatija, pretjerana konzumacija alkohola, kemoterapija ili zlouporaba lijekova te neuralgija trigemina.

Specifični simptomi neuropatske boli su mehanička alodinija i hladna hiperalgezija.

U liječenju neuropatske boli koristi se nekoliko skupina lijekova. U prvu skupinu spadaju adjuvantni lijekovi, a to su antidepresivi i antiepileptici, opiodi i topički agensi. U praksi se najčešće koristi kombinacija dvije ili više vrsta lijekova.

Unatoč brojnim randomiziranim, placebo-kontroliranim studijama na području neuropatske boli, medikamentozno liječenje neuropatske boli još uvijek nije zadovoljavajuće, te se samo u 50% pacijenata sa neuropatskom boli postiže zadovoljavajuća analgezija.

ključne riječi: neuropatska bol; etiologija; liječenje.